Erratum to "How to treat male breast cancer" [The Breast 16S2 (2007) S147-S154] (DOI:10.1016/j.breast.2007.07.024);How to treat male breast cancer

Breast

Volumn 16, Issue 2 SUPPL., 2007, Pages 147-154

  Kamila, Czene ^a   Jenny, Bergqvist ^b   Per, Hall ^a   Jonas, Bergh ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Department of Oncology Pathology Cancer Center Karolinska   (Sweden)

Author keywords

Adjuvant; Male breast cancer; Metastatic; Review

Indexed keywords

ANASTROZOLE; ANDROGEN; ANTHRACYCLINE DERIVATIVE; ANTIANDROGEN; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; GESTAGEN; LETROZOLE; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ADRENALECTOMY; AGE; ALCOHOL CONSUMPTION; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CLINICAL EXAMINATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG MEGADOSE; EUROPE; FAMILY HISTORY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; HYPOPHYSECTOMY; IMMUNOHISTOCHEMISTRY; KLINEFELTER SYNDROME; LIVER DYSFUNCTION; LYMPH NODE METASTASIS; MALE; MAMMOGRAPHY; MASTECTOMY; MEDICAL INFORMATION; METASTASIS POTENTIAL; NEEDLE BIOPSY; NONHUMAN; OBESITY; ORCHIECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATHOLOGICAL ANATOMY; POSTOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RISK FACTOR; TESTIS DISEASE; TREATMENT OUTCOME;

EID: 35748982905     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2008.01.001     Document Type: Erratum

References (64)

1. Schwartsmann G., Ratain M.J., Cragg G.M., et al. Anticancer drug discovery and development throughout the world. J Clin Oncol 20 (2002) 47S-59S
2. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
3. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 (2005) 2087-2106
4. Fossati R., Confalonieri C., Torri V., et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systemic review of published randomized trial involving 31,510 women. J Clin Oncol 16 (1998) 3439-3460
5. Fentiman I.S., Fourquet A., and Hortobagyi G.N. Male breast cancer. Lancet 367 (2006) 595-604
6. Ravdin P, Cronin K, Howlander N, Chlebowski R, Berry D. A sharp decrease in breast cancer incidence in the United States in 2003. In: 29th annual San Antonio breast cancer symposium, San Antonio, TX, Breast Cancer Research Treatment, vol. 100. Berlin: Springer; 2006. p. S6, abstract 5.
7. Anderson W.F., Althuis M.D., Brinton L.A., and Devesa S.S. Is male breast cancer similar or different than female breast cancer?. Breast Cancer Res Treat 83 (2004) 77-86
8. Goss P.E., Reid C., Pintilie M., Lim R., and Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 85 (1999) 629-639
9. Giordano S.H., Cohen D.S., Buzdar A.U., Perkins G., and Hortobagyi G.N. Breast carcinoma in men: a population-based study. Cancer 101 (2004) 51-57
10. El-Tamer M.B., Komenaka I.K., Troxel A., et al. Men with breast cancer have better disease-specific survival than women. Arch Surg 139 (2004) 1079-1082
11. La Vecchia C., Levi F., and Lucchini F. Descriptive epidemiology of male breast cancer in Europe. Int J Cancer 51 (1992) 62-66
12. Harnden D., Maclean N., and Langlands A. Carcinoma of the breast and Klinefelter's syndrome. J Med Genet 8 (1971) 460-461
13. Hultborn R., Hanson C., Kopf I., Verbiene I., Warnhammar E., and Weimarck A. Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Res 17 (1997) 4293-4297
14. Cutuli B. Strategies in treating male breast cancer. Expert Opin Pharmacother 8 (2007) 193-202
15. Cutuli B., Lacroze M., Dilhuydy J.M., et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 31A (1995) 1960-1964
16. Donegan W.L., Redlich P.N., Lang P.J., and Gall M.T. Carcinoma of the breast in males: a multiinstitutional survey. Cancer 83 (1998) 498-509
17. Macdonald G., Paltiel C., Olivotto I.A., and Tyldesley S. A comparative analysis of radiotherapy use and patient outcome in males and females with breast cancer. Ann Oncol 16 (2005) 1442-1448
18. Salvadori B., Saccozzi R., Manzari A., et al. Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer 30A (1994) 930-935
19. Nahleh Z., and Girnius S. Male breast cancer: a gender issue. Nat Clin Pract Oncol 3 (2006) 428-437
20. Albo D., Ames F.C., Hunt K.K., Ross M.I., Singletary S.E., and Kuerer H.M. Evaluation of lymph node status in male breast cancer patients: a role for sentinel lymph node biopsy. Breast Cancer Res Treat 77 (2003) 9-14
21. Cimmino V.M., Degnim A.C., Sabel M.S., Diehl K.M., Newman L.A., and Chang A.E. Efficacy of sentinel lymph node biopsy in male breast cancer. J Surg Oncol 86 (2004) 74-77
22. De Cicco C., Baio S.M., Veronesi P., et al. Sentinel node biopsy in male breast cancer. Nucl Med Commun 25 (2004) 139-143
23. Hill A.D., Borgen P.I., and Cody III H.S. Sentinel node biopsy in male breast cancer. Eur J Surg Oncol 25 (1999) 442-443
24. Boughey J.C., Bedrosian I., Meric-Bernstam F., et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg 203 (2006) 475-480
25. Willsher P.C., Leach I.H., Ellis I.O., Bourke J.B., Blamey R.W., and Robertson J.F. A comparison outcome of male breast cancer with female breast cancer. Am J Surg 173 (1997) 185-188
26. Gennari R., Curigliano G., Jereczek-Fossa B.A., et al. Male breast cancer: a special therapeutic problem. Anything new? (Review). Int J Oncol 24 (2004) 663-670
27. Hooning M.J., Botma A., Aleman B.M., et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99 (2007) 365-375
28. Bergh J., Jönsson P., Glimelius B., and Nygren P. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 40 (2001) 253-281
29. Scholl S., Fourguet A., Asselain B., et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A (1994) 645-652
30. Powles T., Hickish T., Markris A., et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13 (1995) 547-552
31. Mauriac L., MacGrogan G., Avril A., et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10 (1999) 47-52
32. Bear H.D., Anderson S., Brown A., et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21 (2003) 4165-4174
33. Smith I.E., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate Preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23 (2005) 5108-5116
34. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 (2001) 3808-3816
35. Buzdar A.U., Ibrahim N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23 (2005) 3676-3685
36. Ribeiro G., Swindell R., Harris M., Banerjee S., and Cramer A. A review of the management of the male breast carcinoma based on an analysis of 420 treated cases. Breast 5 (1996) 141-146
37. Nordenskjold B., Rosell J., Rutqvist L.E., et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst 97 (2005) 1609-1610
38. Handesman D. Androgen action and pharmacologic uses. In: Degroot A, editor. Endocrinology. 2001. p. 2232-42.
39. Mauras N., O'Brien K.O., Klein K.O., and Hayes V. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 85 (2000) 2370-2377
40. Trunet P.F., Mueller P., Bhatnagar A.S., Dickes I., Monnet G., and White G. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J Clin Endocrinol Metab 77 (1993) 319-323
41. Turner K.J., Morley M., Atanassova N., Swanston I.D., and Sharpe R.M. Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocrinol 164 (2000) 225-238
42. Giordano S.H., and Hortobagyi G.N. Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 24 (2006) e42-e43
43. O'Malley C.D., Prehn A.W., Shema S.J., and Glaser S.L. Racial/ethnic differences in survival rates in a population-based series of men with breast carcinoma. Cancer 94 (2002) 2836-2843
44. Steinitz R., Katz L., and Ben-Hur M. Male breast cancer in Israel: selected epidemiologic aspects. J Med Sci 17 (1981) 816-821
45. Nance K.V., and Reddick R.L. In situ and infiltrating lobular carcinoma of the male breast. Hum Pathol 20 (1989) 1220-1222
46. Michaels B.M., Nunn C.R., and Roses D.F. Lobular carcinoma of the male breast. Surgery 115 (1994) 402-405
47. Giordano S.H., Perkins G.H., Broglio K., et al. Adjuvant systemic therapy for male breast carcinoma. Cancer 104 (2005) 2359-2364
48. Patel II H.Z., Buzdar A.U., and Hortobagyi G.N. Role of adjuvant chemotherapy in male breast cancer. Cancer 64 (1989) 1583-1585
49. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med 353 (2005) 1673-1684
50. Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 (2007) 29-36
51. Jaiyesimi I.A., Buzdar A.U., Sahin A.A., and Ross M.A. Carcinoma of the male breast. Ann Intern Med 117 (1992) 771-777
52. Zabolotny B.P., Zalai C.V., and Meterissian S.H. Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol 90 (2005) 26-30
53. Giordano S.H., Valero V., Buzdar A.U., and Hortobagyi G.N. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 25 (2002) 235-237
54. Munoz de Toro M.M., Maffini M.V., Kass L., and Luque E.H. Proliferative activity and steroid hormone receptor status in male breast carcinoma. J Steroid Biochem Mol Biol 67 (1998) 333-339
55. Murphy C.E., Carder P.J., Lansdown M.R., and Speirs V. Steroid hormone receptor expression in male breast cancer. Eur J Surg Oncol 32 (2006) 44-47
56. Nahleh Z.A. Hormonal therapy for male breast cancer: a different approach for a different disease. Cancer Treat Rev 32 (2006) 101-105
57. Yap H.Y., Tashima C.K., Blumenschein G.R., Hortobagyi G.N., and Eckles N. Chemotherapy for advanced male breast cancer. JAMA 243 (1980) 1739-1741
58. Rudlowski C., Rath W., Becker A.J., Wiestler O.D., and Buttner R. Trastuzumab and breast cancer. N Engl J Med 345 (2001) 997-998
59. Rudlowski C., Friedrichs N., Faridi A., et al. Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 84 (2004) 215-223
60. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23 (2005) 4265-4274
61. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 344 (2001) 783-792
62. Franco A, Col N, Chlebowski R. Discordance in estrogen (ER) and progestin receptor (PR) status between primary metastatic brast cancer: a meta-analysis, In: Perry M, editors. 40th annual meeting of the ASCO, New Orleans, LA, vol. 22, no. 14S, 2004. p. 11, abstract 539.
63. Gancberg D., Di Leo A., Cardoso F., et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13 (2002) 1036-1043
64. Meng S., Tripathy D., Shete S., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101 (2004) 9393-9398